Business
Appointment of a Broker
Appointment of a Broker.
About this update from Faron Pharmaceuticals Oy
[{"type":"text","content":"\n \n \n \n RNS Number : 7238T\n Faron Pharmaceuticals Oy\n 29 March 2021\n \n \n \n \n Faron Pharmaceuticals Oy\n \n \n (\"Faron\" or the \"Company\")\n \n \n Appointment of a Broker\n \n \n \n \n \n \n Company announcement, 29 March 2021 at 9.00 AM (EET)\n \n \n \n \n \n \n TURKU - FINLAND \n \n - Faron Pharmaceuticals Oy (First North: FARON, AIM: FARN), the clinical stage biopharmaceutical company, \n is pleased to announce the appointment of \n Peel Hunt LLP \n as the Company's sole Broker with effect from today.\n \n \n \n \n \n \n \n \n For more information please contact:\n \n \n \n \n \n Faron Pharmaceuticals Oy\n \n \n Dr Markku Jalkanen, Chief Executive Officer\n \n \n \n \n [email protected]\n \n \n \n \n \n \n \n \n \n Peel Hunt LLP\n \n \n , Broker\n \n \n \n \n \n \n Dr \n Christopher Golden\n \n \n D: +44 (0)20 3597 8672\n \n \n M: +44 (0)7703 795 926\n \n \n \n \n \n Cairn Financial Advisers LLP, Nomad\n \n \n Sandy Jamieson, Jo Turner, Mark Rogers\n \n \n Phone: +\n 44 207 213 0880\n \n \n \n \n \n Sisu Partners Oy, Certified Adviser on Nasdaq First North\n \n \n Juha Karttunen\n \n \n Phone: +358 40 555 4727\n \n \n Jukka Järvelä\n \n \n Phone: +358 50 553 8990\n \n \n \n \n \n Consilium Strategic Communications\n \n \n Mary-Jane Elliott, David Daley, Lindsey Neville\n \n \n Phone: +44 (0)20 3709 5700\n \n \n E-mail: \n \n \n [email protected]\n \n \n \n \n \n \n \n \n \n \n Stern Investor Relations\n \n \n Julie Seidel, Alexa Comai\n \n \n Phone: +1 (212) 362-1200\n \n \n E-mail: \n \n \n [email protected]\n \n \n \n \n \n \n \n \n \n \n \n About Faron Pharmaceuticals Ltd \n \n \n \n \n \n Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs caused by dysfunction of our immune system. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology, organ damage and bone marrow regeneration. Bexmarilimab, a novel anti-Clever-1 humanised antibody, is its investigative precision immunotherapy with the potential to provide permanent immune stimulation for difficult-to-treat cancers through targeting myel...